Xiao Guangxu, Lyu Ming, Wang Yule, He Shuang, Liu Xinyan, Ni Jingyu, Li Lan, Fan Guanwei, Han Jihong, Gao Xiumei, Wang Xiaoying, Zhu Yan
Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, Tianjin, China.
Front Pharmacol. 2019 Jul 5;10:735. doi: 10.3389/fphar.2019.00735. eCollection 2019.
Shuxuening injection (SXNI), one of the pharmaceutical preparations of extract, has significant effects on both ischemic stroke and heart diseases from bench to bedside. Its major active ingredients are ginkgo flavonol glycosides (GFGs) and ginkgolides (GGs). We have previously reported that SXNI as a whole protected ischemic brain and heart, but the active ingredients and their contribution to the therapeutic effects remain unclear. Therefore, we combined experimental and network analysis approach to further explore the specific effects and underlying mechanisms of GFGs and GGs of SXNI on ischemia-reperfusion injury in mouse brain and heart. In the myocardial ischemia-reperfusion injury (MIRI) model, pretreatment with GFGs at 2.5 ml/kg was superior to the same dose of GGs in improving cardiac function and coronary blood flow and reducing the levels of lactate dehydrogenase and aspartate aminotransferase in serum, with an effect similar to that achieved by SXNI. In contrast, pretreatment with GGs at 2.5 ml/kg reduced cerebral infarction area and cerebral edema similarly to that of SXNI but more significantly compared with GFGs in cerebral ischemia-reperfusion injury (CIRI) model. Network pharmacology analysis of GFGs and GGs revealed that tumor necrosis factor-related weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling pathway as an important common mechanism but with differential targets in MIRI and CIRI. In addition, immunohistochemistry and enzyme linked immunosorbent assay (ELISA) assays were performed to evaluate the regulatory roles of GFGs and GGs on the common TWEAK-Fn14 signaling pathway to protect the heart and brain. Experimental results confirmed that TWEAK ligand and Fn14 receptor were downregulated by GFGs to mitigate MIRI in the heart while upregulated by GGs to improve CIRI in the brain. In conclusion, our study showed that GFGs and GGs of SXNI tend to differentially protect brain and heart from ischemia-reperfusion injuries at least in part by regulating a common TWEAK-Fn14 signaling pathway.
舒血宁注射液(SXNI)是提取物的药物制剂之一,从实验室研究到临床应用,对缺血性中风和心脏病均有显著疗效。其主要活性成分是银杏黄酮醇苷(GFGs)和银杏内酯(GGs)。我们之前报道过,舒血宁注射液整体可保护缺血的脑和心脏,但其活性成分及其对治疗效果的贡献仍不清楚。因此,我们结合实验和网络分析方法,进一步探究舒血宁注射液中银杏黄酮醇苷和银杏内酯对小鼠脑和心脏缺血再灌注损伤的具体作用及潜在机制。在心肌缺血再灌注损伤(MIRI)模型中,2.5 ml/kg的银杏黄酮醇苷预处理在改善心脏功能、冠状动脉血流量以及降低血清中乳酸脱氢酶和天冬氨酸转氨酶水平方面优于相同剂量的银杏内酯,其效果与舒血宁注射液相似。相比之下,在脑缺血再灌注损伤(CIRI)模型中,2.5 ml/kg的银杏内酯预处理降低脑梗死面积和脑水肿的效果与舒血宁注射液相似,但比银杏黄酮醇苷更显著。对银杏黄酮醇苷和银杏内酯的网络药理学分析表明,肿瘤坏死因子相关凋亡弱诱导剂(TWEAK)-成纤维细胞生长因子诱导14(Fn14)信号通路是一个重要的共同机制,但在心肌缺血再灌注损伤和脑缺血再灌注损伤中有不同的靶点。此外,进行了免疫组织化学和酶联免疫吸附测定(ELISA)试验,以评估银杏黄酮醇苷和银杏内酯对共同的TWEAK-Fn14信号通路的调节作用,从而保护心脏和大脑。实验结果证实,银杏黄酮醇苷可下调TWEAK配体和Fn14受体,减轻心脏的心肌缺血再灌注损伤,而银杏内酯则上调它们,改善脑缺血再灌注损伤。总之,我们的研究表明,舒血宁注射液中的银杏黄酮醇苷和银杏内酯至少部分通过调节共同的TWEAK-Fn14信号通路,对脑和心脏的缺血再灌注损伤有不同的保护作用。